Výsledky vyhledávání - "Abderrahim Khomani"

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group

Autor: Marc L. Filion, Anita Bane, John R. Goffin, Desiree Hao, Mark Levine, Scott A. Laurie, Jean M. Seely, Christina L. Addison, Gregory R. Pond, Abderrahim Khomani, Natasha B. Leighl, Ashish Gupta

Publikováno v: Lung Cancer. 104:65-69

Objectives Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). The fibroblast growth factor receptor (FGFR) signaling pathways may be a relevant target in MPM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b225b19764cf0f5aa37f61ca03ad7226
https://doi.org/10.1016/j.lungcan.2016.12.004

Zobrazit plný text záznamu

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Autor: Jamil Khatri, Elke K. Friedman, Gregory R. Jones, Clive Morris, Ramaswamy Govindan, Manu Patel, Michael A. Pritchett, Nitzan Rosenfeld, D. Ross Camidge, K. Howarth, Vincent Plagnol, Steven Boniol, Abderrahim Khomani, Katherine Baker-Neblett, Samir Dalia

Publikováno v: JCO Precision Oncology

PURPOSE Guidelines advocate molecular profiling in the evaluation of advanced non–small-cell lung cancer (NSCLC) and support the use of plasma circulating tumor DNA (ctDNA)-based profiling for patients with insufficient tissue. Thorough prospective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8ac241f361e397c0cb80fef46c6baa1
http://europepmc.org/articles/PMC7450945

Zobrazit plný text záznamu

Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004

Autor: Julie A. Kish, Richard C.K. Jordan, Pedro A. Torres-Saavedra, Quynh-Thu Le, Steven Francis Powell, Minh Tam Truong, Loren K. Mell, Steven L. Chang, Julie E. Bauman, Tian Liu, David Raben, Muhammad Kashif Riaz, Andy J. Minn, Abderrahim Khomani, Stuart J. Wong

Publikováno v: Journal of Clinical Oncology. 37:6065-6065

6065 Background: MEDI4736 (durvalumab), a PD-L1 inhibitor, has shown promising antitumor activity and safety in head and neck squamous cell carcinoma (HNSCC). A phase II/III trial with lead-in component was designed to evaluate the safety and efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82fcc92438d14d3b12025ba83c282d1e
https://doi.org/10.1200/jco.2019.37.15_suppl.6065

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání